Cardiorenal

Do GLP-1 Agonists Help in Heart Failure Without Diabetes?

Quick answer

In HFpEF with obesity (BMI ≥30), semaglutide and tirzepatide produce clinically meaningful improvements in symptoms, 6-minute walk distance, and weight in patients without diabetes. In HFrEF without diabetes, evidence is more limited and FIGHT and LIVE showed neutral-to-concerning effects on ejection fraction, so GLP-1 agonists are not routinely indicated.

Evidence review

Pivotal trials, effect sizes, and the populations they studied. PubMed identifiers link directly to the source.

STEP-HFpEF (2023)

PMID 37622681

529 patients with HFpEF and BMI ≥30, no diabetes

Semaglutide 2.4 mg improved KCCQ-CSS by 7.8 points vs placebo, 6MWD by 17.1 m, weight loss 10.7% over 52 weeks.

SUMMIT (2024)

PMID 39555826

731 patients with HFpEF (EF ≥50%) and obesity (BMI ≥30)

Tirzepatide reduced worsening HF events or CV death vs placebo (HR 0.62, 95% CI 0.41–0.95). KCCQ-CSS improved, systolic BP and CRP fell, weight loss substantial.

FIGHT (2016)

PMID 27483064

300 patients with HFrEF post-hospitalization

Liraglutide did not improve death/HF hospitalization (HR 1.10, 95% CI 0.57–2.14); signal of more arrhythmias. Neutral in non-diabetic subgroup.

Practical decision algorithm

IfThen
HFpEF + BMI ≥30, symptomatic (NYHA II–III), no diabetesAdd semaglutide 2.4 mg weekly or tirzepatide (per SUMMIT titration) as symptom and weight therapy.
HFpEF + T2D + obesityGLP-1 RA preferred (dual metabolic and CV benefit). Continue SGLT2 inhibitor and MRA.
HFrEF without diabetesGLP-1 RA not routinely recommended. Prioritize the four HFrEF pillars.
HFrEF + obesity where weight loss would enable transplant listing or device candidacyIndividualized decision; monitor EF, HR, and arrhythmia burden closely.

Guideline position

2024 focused ESC HF update: GLP-1 RA (semaglutide) reasonable in HFpEF with obesity (Class 2a). ACC 2024 expert consensus: GLP-1 RA added to HFpEF + obesity regimens is appropriate. No guideline endorsement for HFrEF without diabetes.

Contraindications and cautions

  • Personal or family history of medullary thyroid carcinoma or MEN2
  • Prior severe GLP-1 hypersensitivity
  • Gastroparesis (relative — may worsen)
  • Severe HFrEF with unstable hemodynamics
  • Pregnancy

Frequently asked questions

Is the benefit in STEP-HFpEF independent of weight loss?
Partly. Mediation analyses attribute about 60% of symptom benefit to weight loss; the remainder likely reflects direct cardiometabolic effects, including reduced inflammation and plasma volume.
Should I stop the GLP-1 if weight loss plateaus?
No — the HF outcome benefit appears independent of ongoing weight loss once achieved. Maintenance dosing is recommended per trial protocols.
Can I combine with SGLT2 inhibitor in HFpEF?
Yes — mechanistically complementary. STEP-HFpEF allowed SGLT2 inhibitor use in ~20% and benefit was preserved. No head-to-head, but combination is reasonable when symptom burden persists.
How do I handle GI side effects in frail HFpEF patients?
Slow titration (every 4 weeks minimum), ensure adequate hydration, monitor weight closely. Nausea usually resolves by week 8. Discontinue if orthostasis or AKI develops.
What about semaglutide after HF hospitalization?
STEP-HFpEF excluded recent HF hospitalization (<30 days). Wait for stabilization before initiating; focus on diuretic and four-pillar optimization first.

Further reading

Evidence-Based Medicine

GLP-1 Receptor Agonists Beyond Diabetes: Cardiovascular and Renal Evidence

Evidence-Based Medicine

SGLT2 Inhibitors in Heart Failure: Evidence, Dosing, and Clinical Decision Points

Evidence-Based Medicine

Obesity Pharmacotherapy: Semaglutide, Tirzepatide, and Combination Approaches

Back to all decision points